News coverage about Great Basin Scientific (NASDAQ:GBSN) has trended somewhat positive recently, according to Accern. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Great Basin Scientific earned a daily sentiment score of 0.23 on Accern’s scale. Accern also assigned news articles about the medical research company an impact score of 0 out of 100, meaning that recent news coverage is extremely unlikely to have an impact on the company’s share price in the next several days.

Shares of Great Basin Scientific (NASDAQ GBSN) traded up 2.1739% during trading on Thursday, reaching $0.1175. 522,989 shares of the company were exchanged. The stock’s market capitalization is $8695.00. The company has a 50 day moving average price of $0.29 and a 200-day moving average price of $11.97. Great Basin Scientific has a one year low of $0.10 and a one year high of $906,009.13.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at

Great Basin Scientific Company Profile

Great Basin Scientific, Inc is a molecular diagnostic testing company. The Company is focused on the development and commercialization of its molecular diagnostic platform designed to test for infectious diseases, especially hospital-acquired infections. Its commercially available tests are clostridium difficile (C.

Insider Buying and Selling by Quarter for Great Basin Scientific (NASDAQ:GBSN)

Receive News & Stock Ratings for Great Basin Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Great Basin Scientific Inc and related stocks with our FREE daily email newsletter.